These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12584041)

  • 1. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.
    Fahrleitner A; Prenner G; Leb G; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Portugaller HR; Berghold A; Dobnig H
    Bone; 2003 Jan; 32(1):96-106. PubMed ID: 12584041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.
    Fahrleitner-Pammer A; Dobnig H; Piswanger-Soelkner C; Bonelli C; Dimai HP; Leb G; Obermayer-Pietsch B
    Wien Klin Wochenschr; 2003 May; 115(9):291-7. PubMed ID: 12793029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
    Rogers A; Saleh G; Hannon RA; Greenfield D; Eastell R
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4470-5. PubMed ID: 12364420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
    Valero C; Olmos JM; Rivera F; Hernández JL; Vega ME; Macías JG
    Calcif Tissue Int; 2006 Jun; 78(6):343-7. PubMed ID: 16830204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
    Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
    Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover.
    Uemura H; Yasui T; Umino Y; Niki H; Takikawa M; Saito S; Furumoto H; Irahara M
    Bone; 2003 Nov; 33(5):860-6. PubMed ID: 14623063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
    Indridason OS; Franzson L; Sigurdsson G
    Osteoporos Int; 2005 Apr; 16(4):417-23. PubMed ID: 15776220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
    Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study.
    Ueland T; Brixen K; Mosekilde L; Mosekilde L; Flyvbjerg A; Bollerslev J
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1014-8. PubMed ID: 12629078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.
    Oh KW; Rhee EJ; Lee WY; Kim SW; Oh ES; Baek KH; Kang MI; Choi MG; Yoo HJ; Park SW
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):244-9. PubMed ID: 15272921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.
    Grigorie D; Neacşu E; Marinescu M; Popa O
    Rom J Intern Med; 2003; 41(4):409-15. PubMed ID: 15526523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.
    Franck H; Meurer T; Hofbauer LC
    J Rheumatol; 2004 Nov; 31(11):2236-41. PubMed ID: 15517638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang Zh; Sun LH; Xu MY; Chen JL
    Calcif Tissue Int; 2005 Jan; 76(1):1-6. PubMed ID: 15455183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.
    Sasaki N; Kusano E; Ando Y; Nemoto J; Iimura O; Ito C; Takeda S; Yano K; Tsuda E; Asano Y
    Bone; 2002 Jun; 30(6):853-8. PubMed ID: 12052453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios.
    Jørgensen HL; Kusk P; Madsen B; Fenger M; Lauritzen JB
    J Bone Miner Metab; 2004; 22(2):132-8. PubMed ID: 14999524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.